The Food and Drug Administration has approved a new drug applicationfor Gastromark, a gastrointestinal MRI contrast agent developedby Advanced Magnetics of Cambridge, MA. Gastromark is a superparamagneticoral contrast agent that has been licensed to
The Food and Drug Administration has approved a new drug application
for Gastromark, a gastrointestinal MRI contrast agent developed
by Advanced Magnetics of Cambridge, MA. Gastromark is a superparamagnetic
oral contrast agent that has been licensed to Mallinckrodt Medical
of St. Louis. The agent is marketed in Western Europe by Guerbet
under the trade name Lumirem. Gastromark will be priced at about
$25 per 300 mL, according to Jerome Goldstein, president and CEO
of Advanced Magnetics. Either 600 or 900 mL will likely be administered,
bringing the total cost to between $50 and $75 per patient.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.